Eiger BioPharmaceuticals, Inc. (EIGR): Price and Financial Metrics

Eiger BioPharmaceuticals, Inc. (EIGR): $5.81

0.01 (+0.17%)

POWR Rating

Component Grades








Add EIGR to Watchlist
Sign Up

Industry: Biotech




#168 of 370

in industry

EIGR Price/Volume Stats

Current price $5.81 52-week high $57.90
Prev. close $5.80 52-week low $5.12
Day low $5.81 Volume 4,500
Day high $6.40 Avg. volume 7,138
50-day MA $6.50 Dividend yield N/A
200-day MA $15.71 Market Cap 8.59M

EIGR Stock Price Chart Interactive Chart >


  • EIGR scores best on the Value dimension, with a Value rank ahead of 83.28% of US stocks.
  • EIGR's strongest trending metric is Quality; it's been moving up over the last 68 days.
  • EIGR ranks lowest in Stability; there it ranks in the 5th percentile.

EIGR Stock Summary

  • EIGR has a market capitalization of $10,918,632 -- more than approximately just 5.78% of US stocks.
  • The capital turnover (annual revenue relative to shareholder's equity) for EIGR is -9.14 -- better than just 1.74% of US stocks.
  • The volatility of EIGER BIOPHARMACEUTICALS INC's share price is greater than that of 93.62% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to EIGER BIOPHARMACEUTICALS INC, a group of peers worth examining would be HYLN, CRDF, DBVT, BNTC, and MRSN.
  • EIGR's SEC filings can be seen here. And to visit EIGER BIOPHARMACEUTICALS INC's official web site, go to www.eigerbio.com.

EIGR Valuation Summary

  • In comparison to the median Healthcare stock, EIGR's price/earnings ratio is 100.34% lower, now standing at -0.1.
  • EIGR's price/sales ratio has moved NA NA over the prior 121 months.

Below are key valuation metrics over time for EIGR.

Stock Date P/S P/B P/E EV/EBIT
EIGR 2023-12-29 0.7 -6.2 -0.1 -0.3
EIGR 2023-12-28 0.8 -7.4 -0.1 -0.3
EIGR 2023-12-27 0.7 -6.2 -0.1 -0.3
EIGR 2023-12-26 0.7 -6.1 -0.1 -0.3
EIGR 2023-12-22 0.6 -5.7 -0.1 -0.3
EIGR 2023-12-21 0.7 -6.0 -0.1 -0.3

EIGR Growth Metrics

    Its year over year net cashflow from operations growth rate is now at -24%.
  • Its 2 year price growth rate is now at -34.85%.
  • Its 3 year net cashflow from operations growth rate is now at -41.31%.
Over the past 15 months, EIGR's revenue has gone up $8,405,000.

The table below shows EIGR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 14.148 -77.528 -93.406
2022-06-30 13.163 -76.228 -88.518
2022-03-31 11.169 -74.868 -85.808
2021-12-31 12.142 -71.342 -33.917
2021-09-30 8.782 -70.092 -30.955
2021-06-30 5.743 -64.94 -24.412

EIGR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EIGR has a Quality Grade of F, ranking ahead of 1.43% of graded US stocks.
  • EIGR's asset turnover comes in at 0.037 -- ranking 341st of 682 Pharmaceutical Products stocks.
  • ATNM, MNOV, and ATRA are the stocks whose asset turnover ratios are most correlated with EIGR.

The table below shows EIGR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.037 0.944 -0.198
2021-03-31 0.026 0.985 -0.184
2020-12-31 0.000 NA -0.662
2020-09-30 0.000 NA -0.741
2020-06-30 0.000 NA -0.740
2020-03-31 0.000 NA -0.691

EIGR Price Target

For more insight on analysts targets of EIGR, see our EIGR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.33 Average Broker Recommendation 1 (Strong Buy)

Eiger BioPharmaceuticals, Inc. (EIGR) Company Bio

Eiger BioPharmaceutical Inc, formerly Celladon Corporation, is a clinical-stage biotechnology company engaged in the development of cardiovascular gene therapy. The company was founded in 2008 and is based in Palo Alto, California.

EIGR Latest News Stream

Event/Time News Detail
Loading, please wait...

EIGR Latest Social Stream

Loading social stream, please wait...

View Full EIGR Social Stream

Latest EIGR News From Around the Web

Below are the latest news stories about EIGER BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate EIGR as an investment opportunity.

Eiger BioPharmaceuticals Insiders US$2.1m Short Of Breakeven On Stock Purchase

Insiders who purchased US$3.42m worth of Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shares over the past year...

Yahoo | December 4, 2023

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the third quarter 2023 and provided a business update.

Yahoo | November 9, 2023

Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?

Eiger BioPharmaceuticals (EIGR) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial.

William White on InvestorPlace | September 13, 2023

Why Is Sigma Lithium (SGML) Stock Up 14% Today?

Sigma Lithium (SGML) stock is climbing higher on Wednesday after confirming it has received multiple strategic proposals.

William White on InvestorPlace | September 13, 2023

WKHS Stock Alert: The $40,000 Reason Workhorse Is Up Today

Workhorse (WKHS) stock is on the rise Wednesday thanks to a new update from the IRS concerning its electric vehicle (EV) manufacturer status.

William White on InvestorPlace | September 13, 2023

Read More 'EIGR' Stories Here

EIGR Price Returns

1-mo -1.19%
3-mo -43.86%
6-mo -77.58%
1-year -89.42%
3-year -98.10%
5-year -98.53%
YTD -13.73%
2023 -80.97%
2022 -77.26%
2021 -57.77%
2020 -17.52%
2019 46.65%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!